Free Trial

Organovo Q4 2023 Earnings Report

Organovo logo
$2.13 -0.11 (-4.91%)
As of 09:58 AM Eastern

Organovo EPS Results

Actual EPS
-$10.20
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Organovo Revenue Results

Actual Revenue
$0.16 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Organovo Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Remove Ads

Organovo Earnings Headlines

Organovo sees cash runway through the end of FY26
Organovo, Inc.: Organovo Provides Business Update
New “Trump” currency proposed in DC
After a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out first. Warren Buffett sold off 115 million shares of Apple last year.
Organovo Provides Business Update
Organovo Provides Business Update
See More Organovo Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Organovo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Organovo and other key companies, straight to your email.

About Organovo

Organovo (NASDAQ:ONVO), a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

View Organovo Profile

More Earnings Resources from MarketBeat